1.Lineage-specific chimerism analysis in nucleated cells, T cells and natural killer cells after myeloablative allogeneic hematopoietic stem cell transplantation.
Ri Young GOH ; Sung Hyun KIM ; Jin Yeong HAN
Korean Journal of Hematology 2011;46(1):18-23
BACKGROUND: Chimerism analysis is an important tool for assessing the origin of hematopoietic cells after allogeneic stem cell transplantation (allo-SCT) and can be used to detect impending graft rejection and the recurrence of underlying malignant or nonmalignant diseases. METHODS: This study included 24 patients who underwent myeloablative allo-SCT. DNA was extracted from nucleated cells (NCs), T cells, and natural killer (NK) cells, and the chimerism status of these cell fractions was determined by STR-PCR performed using an automated fluorescent DNA analyzer. RESULTS: Twenty-three out of the 24 patients achieved engraftment. Mixed chimerism (MC) in NCs, but not in T cells and NK cells, was significantly correlated with disease relapse. MC in all cell fractions was correlated with mortality. Ten patients (41.6%) developed extensive chronic GVHD. Six patients had MC in T cells, and 3 of them had chronic GVHD. Four patients with MC and relapse received donor lymphocyte infusion (DLI), and among them, 3 had secondary relapse. Further, the chimerism status differed among different cell lineages in 6 patients with myeloid malignancies. CONCLUSION: The implications of MC in lymphocyte subsets are an important area for future research. Chimerism analysis in lineage-specific cells permits detection of relapse and facilitates the monitoring of therapeutic interventions. These results can provide the basic data for chimerism analysis after myeloablative SCT.
Cell Lineage
;
Chimerism
;
DNA
;
Graft Rejection
;
Hematopoietic Stem Cell Transplantation
;
Hematopoietic Stem Cells
;
Humans
;
Killer Cells, Natural
;
Lymphocyte Subsets
;
Lymphocytes
;
Recurrence
;
Stem Cell Transplantation
;
T-Lymphocytes
;
Tissue Donors
2.Trends in Clinical Application of Platelet-Derived Bioproducts
Kyeong-Hee KIM ; Ri-Young GOH ; Yonggon CHO ; Duck CHO
Korean Journal of Blood Transfusion 2024;35(3):196-199
Platelets contain various growth factors and cytokines. Platelet-derived bioproducts, such as platelet-rich plasma (PRP), platelet-rich fibrin (PRF), and platelet lysate (PL), have been developed and used in clinical practice. PRP and PRF are mainly derived from autologous blood and are used in orthopedics, ophthalmology, skin ulcer treatment, and oral surgery. PL is attracting attention as a substitute for fetal bovine serum in cultures for cell therapy. Research and development on platelet lysate production should be carried out, and transfusion medicine professionals must be involved in the clinical utilization of platelet-derived bioproducts.
3.Trends in Clinical Application of Platelet-Derived Bioproducts
Kyeong-Hee KIM ; Ri-Young GOH ; Yonggon CHO ; Duck CHO
Korean Journal of Blood Transfusion 2024;35(3):196-199
Platelets contain various growth factors and cytokines. Platelet-derived bioproducts, such as platelet-rich plasma (PRP), platelet-rich fibrin (PRF), and platelet lysate (PL), have been developed and used in clinical practice. PRP and PRF are mainly derived from autologous blood and are used in orthopedics, ophthalmology, skin ulcer treatment, and oral surgery. PL is attracting attention as a substitute for fetal bovine serum in cultures for cell therapy. Research and development on platelet lysate production should be carried out, and transfusion medicine professionals must be involved in the clinical utilization of platelet-derived bioproducts.
4.Trends in Clinical Application of Platelet-Derived Bioproducts
Kyeong-Hee KIM ; Ri-Young GOH ; Yonggon CHO ; Duck CHO
Korean Journal of Blood Transfusion 2024;35(3):196-199
Platelets contain various growth factors and cytokines. Platelet-derived bioproducts, such as platelet-rich plasma (PRP), platelet-rich fibrin (PRF), and platelet lysate (PL), have been developed and used in clinical practice. PRP and PRF are mainly derived from autologous blood and are used in orthopedics, ophthalmology, skin ulcer treatment, and oral surgery. PL is attracting attention as a substitute for fetal bovine serum in cultures for cell therapy. Research and development on platelet lysate production should be carried out, and transfusion medicine professionals must be involved in the clinical utilization of platelet-derived bioproducts.
5.Trends in Clinical Application of Platelet-Derived Bioproducts
Kyeong-Hee KIM ; Ri-Young GOH ; Yonggon CHO ; Duck CHO
Korean Journal of Blood Transfusion 2024;35(3):196-199
Platelets contain various growth factors and cytokines. Platelet-derived bioproducts, such as platelet-rich plasma (PRP), platelet-rich fibrin (PRF), and platelet lysate (PL), have been developed and used in clinical practice. PRP and PRF are mainly derived from autologous blood and are used in orthopedics, ophthalmology, skin ulcer treatment, and oral surgery. PL is attracting attention as a substitute for fetal bovine serum in cultures for cell therapy. Research and development on platelet lysate production should be carried out, and transfusion medicine professionals must be involved in the clinical utilization of platelet-derived bioproducts.
6.Aspirin Resistance May Not Be Associated with Clinical Outcome after Acute Ischemic Stroke: Comparison with Three Different Platelet Function Assays.
Nam Tae YOO ; Hyo Jin BAE ; Ji Eun KIM ; Ri Young GOH ; Jin Yeong HAN ; Moo Hyeon KIM ; Jae Kwan CHA
Korean Journal of Stroke 2012;14(1):35-42
BACKGROUND: Aspirin resistance (AR) in platelet function assays showed substantial variation depending on the methods used to evaluate it. METHODS: In this study, we prospectively compared the results of Multiplate impedance platelet aggregometry (IPA) with those of light transmission aggregometry (LTA) and VerifyNow(R) system in determination of the prevalence of aspirin resistance (AR) and investigated the correlation between its presence and poor outcome (modified Rankin scale >2) in 105 patients with aspirin after acute ischemic stroke (AIS). RESULTS: After 5 days of using aspirin, 15 patients (14.3%) were classified as aspirin-resistance with the use of IPA, 24 patients (22.9%) by the LTA, and 14 patients (13.3%) by VerifyNow. Good agreement between the results of IPA and VerifyNow, was found (R=0.674, P<0.01). The concordance rate of AR detection was high between VerifyNow and IPA (k=0.72, P<0.01), albeit quite low between LTA and IPA. Regarding on its influence on clinical outcome after AIS, there wasn't any significant relationship between occurrence of poor outcome and the presence of AR in three platelet function assays. CONCLUSION: This study reveals that the incidence of AR in AIS might be highly test-specific. IPA seems to be similar to VerifyNow as a platelet function test.
Aspirin
;
Blood Platelets
;
Electric Impedance
;
Humans
;
Incidence
;
Light
;
Platelet Function Tests
;
Prevalence
;
Prospective Studies
;
Stroke
7.Improving Storage Policy in Korean Public Cord Blood Banks: Comparison of Quality between Long-Term and Short-Term Storage of Cord Blood
Mi Nam LEE ; Kyeong-Hee KIM ; Byoung-Gwon KIM ; Ri-Young GOH ; Jun Nyun KIM
Korean Journal of Blood Transfusion 2020;31(2):119-130
Background:
The decreased use of cord blood units (CBU) due to improvements in haploidentical transplantation is a financial burden for public cord blood banks. Currently, there is no guidance regarding the length of cryopreservation of CBU in Korean public banks. The relative quality of long-term storage CB (LTCB) and short-term storage CB (STCB) needs to be evaluated to establish a storage policy.
Methods:
Thirty-four and thirty-one units of CB cryopreserved for less than one year and up to 14∼15.5 years, respectively, in the Busan Gyeongnam Public Cord Blood Bank were assessed. The total nucleated cells (TNCs), CD34+ cell counts, and colony-forming units-granulocyte monocyte (CFU-GM) were examined. The cell viabilities were evaluated by Eosin-Y exclusion staining and 7-aminoactinomycin D flow cytometry. The number of stored Korean public CB units from 2000 to 2016 was determined and categorized according to TNCs.
Results:
The post-thawing viability of the STCBs measured by flow cytometry was consistently higher than that of the LTCBs (TNCs, 62.5% vs 57.3%; MNCs, 93.1% vs 88.9%; CD34+ cells 95.7% vs 94.0%). The CD34+ cell viability was significantly higher in STCB (P=0.03). The CFU-GM after thawing was higher in STCBs (61.5±23.4 vs 49.9±22.8 [0.95 mm 2 ] P=0.05). Of the 48,161 CB units stored until 2016, Dec, 9,493 (19.7%), which were stored until 2006, had been stored for more than 10 years.
Conclusion
LTCB with a low number of cells (<0.7×10 9 cells) should be considered to exclude from storage for therapeutic purposes to improve the storage efficiency.
8.Evaluating histone H3.1 as a biomarker for acute ischemic stroke: insights into NETs and stroke pathophysiology
Suji PARK ; Jae‑Ryong SHIM ; Ri‑Young GOH ; Dae‑Hyun KIM ; Jin‑Yeong HAN
Blood Research 2024;59():40-
The diagnosis of acute ischemic stroke (AIS) can be challenging when neuroimaging findings are normal or equivo‑ cal. Neutrophil extracellular traps (NETs), particularly histone H3.1, have potential as biomarkers for AIS. This study evaluated NETs, specifically histone H3.1, as diagnostic biomarkers for AIS. This prospective study included 89 patients with AIS and 20 healthy controls. Plasma histone H3.1 levels were measured using the Nu.Q® H3.1 enzyme-linked immunosorbent assay (ELISA). Seven cytokines were analyzed using a bead-based immunoassay. Statistical analy‑ ses were used to compare histone H3.1 levels between groups and evaluate correlations with clinical parameters and cytokines. Histone H3.1 levels were significantly higher in patients with AIS (271.05 ± 33.40 ng/mL) versus controls (95.33 ± 12.86 ng/mL, p < 0.001). Multivariable logistic regression identified H3.1 as an independent risk factor for AIS (p = 0.006), with an area under the curve of 0.907. Significant correlations were found between H3.1, interleukin-6 (0.290, p = 0.013) and vascular cell adhesion molecule 1 (0.297, p = 0.011). In conclusion, the NETs H3.1 ELISA test is a reliable new diagnostic option that supports the diagnosis of AIS.
9.Evaluating histone H3.1 as a biomarker for acute ischemic stroke: insights into NETs and stroke pathophysiology
Suji PARK ; Jae‑Ryong SHIM ; Ri‑Young GOH ; Dae‑Hyun KIM ; Jin‑Yeong HAN
Blood Research 2024;59():40-
The diagnosis of acute ischemic stroke (AIS) can be challenging when neuroimaging findings are normal or equivo‑ cal. Neutrophil extracellular traps (NETs), particularly histone H3.1, have potential as biomarkers for AIS. This study evaluated NETs, specifically histone H3.1, as diagnostic biomarkers for AIS. This prospective study included 89 patients with AIS and 20 healthy controls. Plasma histone H3.1 levels were measured using the Nu.Q® H3.1 enzyme-linked immunosorbent assay (ELISA). Seven cytokines were analyzed using a bead-based immunoassay. Statistical analy‑ ses were used to compare histone H3.1 levels between groups and evaluate correlations with clinical parameters and cytokines. Histone H3.1 levels were significantly higher in patients with AIS (271.05 ± 33.40 ng/mL) versus controls (95.33 ± 12.86 ng/mL, p < 0.001). Multivariable logistic regression identified H3.1 as an independent risk factor for AIS (p = 0.006), with an area under the curve of 0.907. Significant correlations were found between H3.1, interleukin-6 (0.290, p = 0.013) and vascular cell adhesion molecule 1 (0.297, p = 0.011). In conclusion, the NETs H3.1 ELISA test is a reliable new diagnostic option that supports the diagnosis of AIS.
10.Evaluating histone H3.1 as a biomarker for acute ischemic stroke: insights into NETs and stroke pathophysiology
Suji PARK ; Jae‑Ryong SHIM ; Ri‑Young GOH ; Dae‑Hyun KIM ; Jin‑Yeong HAN
Blood Research 2024;59():40-
The diagnosis of acute ischemic stroke (AIS) can be challenging when neuroimaging findings are normal or equivo‑ cal. Neutrophil extracellular traps (NETs), particularly histone H3.1, have potential as biomarkers for AIS. This study evaluated NETs, specifically histone H3.1, as diagnostic biomarkers for AIS. This prospective study included 89 patients with AIS and 20 healthy controls. Plasma histone H3.1 levels were measured using the Nu.Q® H3.1 enzyme-linked immunosorbent assay (ELISA). Seven cytokines were analyzed using a bead-based immunoassay. Statistical analy‑ ses were used to compare histone H3.1 levels between groups and evaluate correlations with clinical parameters and cytokines. Histone H3.1 levels were significantly higher in patients with AIS (271.05 ± 33.40 ng/mL) versus controls (95.33 ± 12.86 ng/mL, p < 0.001). Multivariable logistic regression identified H3.1 as an independent risk factor for AIS (p = 0.006), with an area under the curve of 0.907. Significant correlations were found between H3.1, interleukin-6 (0.290, p = 0.013) and vascular cell adhesion molecule 1 (0.297, p = 0.011). In conclusion, the NETs H3.1 ELISA test is a reliable new diagnostic option that supports the diagnosis of AIS.